Predicting the Response to Sorafenib in Hepatocellular Carcinoma: Where is the Evidence for Phosphorylated Extracellular Signaling-Regulated Kinase (pERK)? by Zhu, Andrew Xiuxuan
 
Predicting the Response to Sorafenib in Hepatocellular Carcinoma:
Where is the Evidence for Phosphorylated Extracellular Signaling-
Regulated Kinase (pERK)?
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Zhu, Andrew X. 2009. Predicting the response to sorafenib in
hepatocellular carcinoma: where is the evidence for
phosphorylated extracellular signaling-regulated kinase (pERK)?
BMC Medicine 7: 42.
Published Version doi://10.1186/1741-7015-7-42
Accessed February 19, 2015 4:17:33 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4739148
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAABioMed  Central
Page 1 of 4
(page number not for citation purposes)
BMC Medicine
Open Access Commentary
Predicting the response to sorafenib in hepatocellular carcinoma: 
where is the evidence for phosphorylated extracellular 
signaling-regulated kinase (pERK)?
Andrew X Zhu
Address: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
Email: Andrew X Zhu - azhu@partners.org
Abstract
The approval of sorafenib and active development of many other molecularly targeted agents in
hepatocellular carcinoma (HCC) have presented a challenge to understand the mechanism of
action of sorafenib and identify predictive biomarkers to select patients more likely to benefit from
sorafenib. The preclinical study by Zhang and celleagues published this month in BMC Medicine
provides preliminary evidence that baseline phosphorylated extracellular signaling-regulated kinase
(pERK) may be a relevant marker to reflect the level of constitutive activation of the RAF/mitogen-
activated protein kinase kinase (MEK)/ERK signaling pathway and has the potential value in
predicting response to sorafenib. The clinical data from the initial single arm phase II study and
preliminary report from the randomized phase III study also suggest the correlation of baseline
archived tumor pERK levels and time to tumor progression in HCC patients. Whether baseline
pERK will prove to be a useful predictive biomarker of response and clinical benefits for sorafenib
in HCC will need to be validated in future large prospective studies.
Commentary
In 2007, Llovet and colleagues first reported the results of
the international, phase III, placebo-controlled Sorafenib
HCC Assessment Randomized Protocol (SHARP) trial,
which demonstrated a longer overall survival (OS) time
and time to tumor progression (TTP) compared to pla-
cebo in patients with advanced hepatocellular carcinoma
(HCC) [1]. As shown in Table 1, the median OS time was
10.7 months in the sorafenib group and 7.9 months in the
placebo group (hazard ratio for the sorafenib group, 0.69;
P < 0.001). The median TTP was 5.5 months in the soraf-
enib group and 2.8 months in the placebo group (P <
0.001). In a subsequent randomized phase III study con-
ducted in Asia, sorafenib also demonstrated a longer OS
and TTP in patients with advanced HCC [2]. These studies
have led to the timely approval of sorafenib in HCC in
many countries worldwide. The development of sorafenib
in HCC has several important implications. First, it vali-
dates the use of molecularly targeted agents in HCC. Sec-
ond, it sets a new standard for ongoing and future clinical
trials in advanced HCC. Now, the challenge is to under-
stand the mechanism of action of this targeted agent and
identify predictive biomarkers to select patients more
likely to benefit from sorafenib. In an article published
this month in BMC Medicine, Zhang and colleagues report
their study assessing the potential role of phosphorylated
extracellular signaling-regulated kinase (pERK) as a pre-
dictive marker in a preclinical HCC model [3].
Sorafenib is an oral multikinase inhibitor that targets
tumor cell proliferation and tumor angiogenesis by inhib-
iting the serine/threonine kinases Raf-1 and B-Raf through
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the canonical Raf/mitogen-activated protein kinase/extra-
cellular signal-regulated kinase (RAF/mitogen-activated
protein kinase kinase (MEK)/ERK) signaling pathway and
the receptor tyrosine kinases (RTK) of vascular endothelial
growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3
and platelet-derived growth factor receptor (PDGFR)α
and β and stem cell factor receptor (KIT) [4,5]. Human
HCC tumors have high expression and enhanced activity
of mitogen-activated protein kinase (MAPK) compared to
the adjacent non-neoplastic liver [6]. Furthermore, treat-
ment of HCC cells with a MEK inhibitor reduces cell pro-
liferation and induces apoptosis [7], whereas
overexpression of activated MEK1 in HepG2 cells
enhances tumor growth in vivo [8]. Unlike malignant
melanoma or other tumor types, BRAF-activating muta-
tions are relatively rare events in HCC [9]. However, Raf
kinase is overexpressed in a high percentage of human
HCC tumors, and the RAF/MEK/ERK pathway can be acti-
vated by major etiologic factors such as hepatitis B virus
(HBV) and hepatitis C virus (HCV) infection [9,10]. In a
series of elegant experiments, Liu and colleagues demon-
strated that sorafenib inhibited the phosphorylation of
MEK and ERK and downregulated cyclin D1 levels in both
PLC/PRF/5 and HepG2 cells [11]. Sorafenib also reduced
the phosphorylation level of eIF4E and downregulated
the antiapoptotic protein Mcl-1 in a MEK/ERK-independ-
ent manner. Consistent with the effects on both MEK/
ERK-dependent and MEK/ERK-independent signaling
pathways, sorafenib inhibited proliferation and induced
apoptosis in both HCC cell lines. In the PLC/PRF/5
xenograft model, sorafenib at 30 mg/kg produced com-
plete tumor growth inhibition. Mechanistically, sorafenib
inhibited the phosphorylation of both ERK and eIF4E,
reduced the microvessel area (assessed by CD34 immuno-
histochemistry), and induced tumor cell apoptosis
(assessed by terminal deoxynucleotidyl transferase-medi-
ated nick-end labeling) in PLC/PRF/5 tumor xenografts.
These findings provide strong support that sorafenib
could target HCC through inhibition of tumor angiogen-
esis and tumor cell proliferation.
The successful clinical development of sorafenib in HCC
and the improved understanding of the mechanism of
action of sorafenib have raised several critical questions.
What are the potential mechanisms of action that lead to
the sorafenib-mediated clinical benefits? Is this due to the
VEGFR blockage, inhibition of RAF/MEK/ERK signaling
pathway, or off target effects? What are the molecular and
clinical predictors of benefits of sorafenib in HCC? In an
article published this month in BMC Medicine, Zhang and
colleagues provided evidence to support the notion that
pERK might be a useful predictive marker in preclinical
HCC model [3]. RAF/MEK/ERK is an important prototyp-
ical signal transduction pathway that is aberrantly acti-
vated in many malignancies [12]. The MEK homologues
MEK1 and MEK2 are dual specificity kinases, uniquely
sharing the consensus kinase motifs of both serine/threo-
nine as well as tyrosine kinases. They exhibit a high degree
of stringency in their ability to phosphorylate their ERK
substrates. Both MEK isoforms sequentially phosphor-
ylate ERK1 and ERK2 at two sites, initially Tyr185 followed
by Thr183 [13]. Therefore, pERK is a key downstream com-
ponent of the RAF/MEK/ERK pathway. Once phosphor-
ylated, pERK can be translocated to the nucleus where it
can regulate gene expression by phosphorylating and
modulating various transcription factors and target genes
[14]. The key strategic location of pERK provides the the-
oretical basis for its potential role to predict response to
agents including sorafenib that inhibit the RAF/MEK/ERK
pathway. Using different HCC cell lines (SMMC-7721,
MHCC97-L, MHCC97-H and HCCLM6), Zhang et al.
assessed the pERK expression by immunocytochemical
quantification and found that basal pERK levels increased
stepwise in these cell lines in accordance with their meta-
static potential. Sorafenib inhibited ERK phosphorylation
in a dose-dependent manner in these cell lines at a con-
centration between 5 and 20 μM and the degree of inhibi-
tion correlated with their basal pERK expression level.
They further demonstrated that the effects of sorafenib on
cell proliferation correlated significantly with basal pERK
levels. To explore if this correlation was linked to pERK,
Table 1: Sorafenib HCC Assessment Randomized Protocol (SHARP) [1] and Asia-Pacific [2] study
SHARP [1] Asia-Pacific [2]
Endpoint Sorafenib vs placebo Sorafenib vs placebo
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
OS 10.7 vs 7.9 months,
0.69 (0.55 to 0.87)
< 0.001 6.5 vs 4.2 months, 
0.68 (0.50 to 0.93)
0.014
TTSP 1.08 (0.88 to 1.31) 0.768 0.90 (0.67 to 1.22) 0.50
TTP 5.5 vs 2.8 months,
0.58 (0.45 to 0.74)
< 0.001 2.8 vs 1.4 months,
0.57 (0.42 to 0.79)
< 0.001
RR 2% vs 1% 3.3% vs 1.3%
OS = overall survival; RR = response rate; TTP = time to tumor progression; TTSP = time to symptomatic progression.BMC Medicine 2009, 7:42 http://www.biomedcentral.com/1741-7015/7/42
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the authors showed that by reducing the basal ERK phos-
phorylation level in MHCC97-H with U0126, a selective
inhibitor of MEK1/2, they could render these cells less
sensitive to sorafenib-mediated growth inhibition. These
preclinical findings lend support to the initial report from
the phase II study of sorafenib in advanced HCC, in which
33 out of 137 enrolled patients had pretreatment archived
tumor tissue available for pERK staining and correlative
analyses. In the majority of tumor samples, staining was
generally most intense within the nucleus of tumor cells
and there was a significant difference in TTP between
patients with higher tumor cell pERK staining intensity,
versus those with lower intensity [15].
Is the evidence strong enough to support the use of pERK
as a predictive biomarker for sorafenib in HCC? Although
this is an intuitive biomarker candidate for sorafenib, and
the study of Zhang and colleagues provides promising in
vitro results, much has to be done before pERK evaluation
will become a useful biomarker. Future mechanistic study
should assess the link of perturbing pERK pathway in each
cell line with drug sensitivity. In addition, the expression
of other signaling molecules should be evaluated to make
certain that the sensitivity to sorafenib is indeed depend-
ent on pERK expression. The clinical evidence to support
the use of pERK as a predictive marker for sorafenib in
HCC is also preliminary. Future studies should evaluate
pERK expression in large numbers of patients and deter-
mine if this biomarker has predictive or prognostic value.
Identification of potential predictive and surrogate mark-
ers in patients receiving sorafenib and other targeted
agents remains an area of active investigation. In a prelim-
inary presentation at the American Association for the
Study of Liver Diseases (ASSLD) meeting in 2008, Llovet
and colleagues reported the early results of assessing
potential useful predictive biomarkers in the SHARP study
[16]. They found that sorafenib significantly decreased
plasma levels of soluble c-KIT, sVEGFR2, sVEGFR3 and
increased VEGF levels at 12 weeks. HCC patients with
baseline high levels of soluble c-KIT showed a trend to
better response to sorafenib in terms of OS and TTP. In
addition, baseline higher pERK immunostaining corre-
lated with a trend towards longer TTP. We are eagerly wait-
ing the final report of the correlative analyses from this
randomized study. Finally, in an attempt to evaluate the
mechanisms of action and to identify useful biomarkers,
extensive correlative studies have been performed in two
phase II studies of sunitinib (a multitargeted tyrosine
kinase inhibitor with overlapping but not identical spec-
trum with sorafenib) in HCC [17,18]. They identified
associations between soluble c-KIT, interleukin (IL)6 and
other cytokines and OS and progression free survival in
advanced HCC patients. Collectively, these circulating
biomarker data suggest a critical role for the balance
between angiogenic and inflammatory pathways in HCC
response and resistance to treatment with tyrosine kinase
inhibitors. Successful modulation of these inflammatory
markers might be critical for achieving treatment response
with sunitinib and potentially other antiangiogenic
agents including sorafenib.
In conclusion, the study by Zhang et al. provides addi-
tional evidence that baseline pERK may be a relevant
marker to reflect the level of constitutive activation of the
RAF/MEK/ERK signaling pathway and has the potential
value in predicting response to sorafenib. The clinical data
on the correlation of pERK and TTP is interesting, but pre-
liminary. Whether baseline pERK will prove to be a useful
predictive biomarker of response and clinical benefits for
sorafenib in HCC will need to be validated in future large
prospective studies.
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